Milestone Scientific (MLSS) AI Stock Analysis

• Market Cap: $39.28M
• Dividend Yield: N/A
• Average Volume (3M): 102.58K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.70
• Revenue Growth: 7.84%
• EPS Growth: -43.00%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.02
• Shares Outstanding: 78,559,150
• 10 Day Avg. Volume: 166,737
• 30 Day Avg. Volume: 102,580
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.32
• Enterprise Value/Revenue: 5.73
• Enterprise Value/Gross Profit: 7.87
• Enterprise Value/Ebitda: -7.59
• 1Y Price Target: $1.25
• Price Target Upside: 165.96% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 46 Neutral
• Price Target: $0.50 ▲(6.38% Upside)

Milestone Scientific's overall stock score is primarily impacted by its challenging financial performance, characterized by ongoing losses and cash flow issues. The neutral technical indicators and negative valuation metrics further weigh on the score. However, the recent appointment of a new CEO with a strong track record provides a positive outlook for future strategic execution.

Positive Factors

Leadership Change

The appointment of Eric C. Hines as CEO brings a strategic shift, leveraging his experience to enhance sales execution and market expansion, crucial for long-term growth.

Product Innovation

Milestone's innovative CompuFlo® technology offers a competitive edge in the medical device market, promoting patient safety and potentially increasing market share.

Revenue Streams

A diverse revenue model with direct sales and recurring income from consumables provides a stable financial base and potential for sustained growth.

Negative Factors

Financial Performance

Ongoing losses and negative cash flows indicate financial instability, which could hinder the company's ability to invest in growth and innovation.

Cash Flow Issues

Persistent negative cash flows suggest difficulties in generating cash, impacting the company's ability to fund operations and strategic initiatives.

Return on Equity

A negative ROE indicates poor returns on shareholder investments, raising concerns about the company's ability to deliver value to its investors.

Milestone Scientific Business Overview & Revenue Model

Company Description

Milestone Scientific Inc. designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates in two segments, Dental and Medical. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. The company also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, it provides CompuFlo Epidural, a computer controlled anesthesia system for use in various medical applications. Further, the company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Livingston, New Jersey.

How the Company Makes Money

Milestone Scientific generates revenue primarily through the sale of its medical devices and related consumables. The main revenue streams include direct sales of the CompuFlo® system to dental and medical practitioners, as well as recurring revenue from the sale of disposable components that accompany the device. Additionally, the company may benefit from partnerships with healthcare organizations and distributors that expand market reach and enhance sales opportunities. Licensing agreements and collaborations with research institutions further contribute to its earnings by allowing Milestone to leverage its technology and expertise in broader applications.

Milestone Scientific Financial Statement Overview

Summary

Milestone Scientific demonstrates strong gross profit margins and low leverage, but persistent net losses and negative cash flows highlight ongoing financial challenges. The company needs to enhance revenue growth and improve operational efficiencies to achieve profitability and strengthen its financial position.

Income Statement

Milestone Scientific shows a declining revenue trend with a steep drop of 34.52% from 2023 to 2024. Gross profit margins are strong at 100% for 2024, indicating effective cost control. However, the net profit margin remains negative due to consistent operating losses, despite slight improvements in EBIT and EBITDA margins.

Balance Sheet

The company's debt-to-equity ratio is low at 0.06, indicating minimal leverage, a positive sign of financial stability. However, the return on equity remains negative, reflecting ongoing losses. Equity ratio remains robust, showcasing a solid foundation of equity in its asset base.

Cash Flow

Operating cash flow has improved from a severe deficit but remains negative, showing challenges in generating cash from core operations. Free cash flow is also negative, indicating a strain on liquidity. Positive investing cash flow suggests asset divestment or reduced investment, which could impact future growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.08M	8.63M	9.83M	8.81M	10.30M	5.44M
Gross Profit	6.61M	6.43M	6.79M	4.90M	6.31M	3.62M
EBITDA	-6.86M	-6.72M	-6.96M	-8.68M	-7.30M	-7.36M
Net Income	-6.97M	-4.71M	-6.93M	-8.71M	-7.12M	-7.49M
Balance Sheet
Total Assets	8.05M	9.80M	11.37M	13.70M	19.81M	19.57M
Cash, Cash Equivalents and Short-Term Investments	1.27M	3.26M	5.95M	8.72M	14.76M	14.22M
Total Debt	1.09M	349.05K	395.98K	497.04K	586.59K	942.60K
Total Liabilities	4.71M	3.96M	3.36M	3.70M	3.59M	3.46M
Stockholders Equity	3.34M	5.83M	8.01M	10.23M	16.37M	16.20M
Cash Flow
Free Cash Flow	-5.26M	-2.93M	-5.33M	-6.04M	-4.03M	-7.01M
Operating Cash Flow	-5.26M	-2.92M	-5.33M	-6.03M	-4.02M	-6.98M
Investing Cash Flow	-2.98M	2.97M	-2.97M	-8.53K	-15.19K	-21.44K
Financing Cash Flow	789.19K	233.77K	2.56M	-8.54K	4.57M	19.71M

Milestone Scientific Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.47
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLSS, the sentiment is Negative. The current price of 0.47 is below the 20-day moving average (MA) of 0.58, below the 50-day MA of 0.58, and below the 200-day MA of 0.87, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 29.24 is Positive, neither overbought nor oversold. The STOCH value of 22.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MLSS.

Milestone Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INFU	70 Outperform	209.37M	43.21	9.30%	―	8.13%	1293.06%
KRMD	59 Neutral	182.63M	-40.18	-27.32%	―	19.57%	61.81%
HBIO	49 Neutral	19.94M	-0.34	-364.88%	―	-12.24%	-427.45%
MLSS	46 Neutral	$39.28M	―	-123.50%	―	7.84%	-43.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Milestone Scientific Corporate Events

Milestone Scientific Appoints Eric C. Hines as CEO

On August 1, 2025, Milestone Scientific Inc. announced the appointment of Eric C. Hines as the new Chief Executive Officer, effective immediately. Hines, with over 25 years of leadership experience in scaling sales-driven enterprise software companies, is expected to drive the company’s next phase of commercial execution. His appointment comes at a pivotal moment as Milestone Scientific aims to expand its presence in the medical and dental markets, leveraging recent achievements in reimbursement and the potential of its CompuFlo® technology. The company believes Hines’s expertise will help accelerate the adoption of their technology and guide them in pursuing new clinical indications and global opportunities.